New Delhi, India, July 24, 2015 --(PR.com
)-- DelveInsight, the leading market research and consulting company has added new report, Acne Vulgaris-API Insights, 2015 to its portfolio. With this launch Delveinsight now has 400+ Reports on Indication API Insight. DelveInsight is the only company that promulgates API Insight Reports. In addition to this their research expertise provides their clients with up to date information of market till date order has been placed.
The Indication API Insight Reports provides client with details on global Acne Vulgaris drugs marketed and API Manufacturers details. It comprehensively includes:
· Global competitive and therapeutic assessment on marketed drugs, API manufacturers, patent expiration and exclusivity
· Information on United States Drug Master File (USDMF) and Europe DMF filed by countries worldwide
· Coverage of marketed drugs along with Global API Manufacturers and regulatory filings across Europe, US, India and China
· The report provides information on global Market therapeutics scenario, regulatory information, marketing status and detail of product profiles for marketed products with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical description.
· Global drug sales forecast up to 2016.
The Reports give opportunities to generic manufacturers and also helps API industry to track closest competitors and prioritizing new drug intermediates to add to the portfolio when drug goes off patent. The detail sales forecasted data will play pivotal role in partnering and collaborations by analyzing the future state of the market. In addition to this Acne Vulgaris-API Insights, 2015 report will be of great value for smaller companies looking to out-license their technologies in global Pharma market.
DelveInsight is offering the Report at a price of USD 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License.